Evaluation of Dermaheal Ointment Effects on Foot Ulcers in diabetic patients
Design
In this study, diabetic patients either type 1 or type 2 with a nonhealing wound at the Clinic of Diabetes Research Center, Endocrinology and Metabolism Research, Tehran University of Medical Sciences. Patients are then randomly divided into two groups A and B (Dermahil or Eucerine) using a randomized randomized table. In both groups wound and surrounding tissues will be irrigated by normal sterile saline and then dried with sterile gauze. Wounds will be treated by Placebo or Dermaheal Ointment under A or B Ointments. Ointments should be used for 4 consecutive weeks once a day with changing the dressing. At the end of each week, based on checklists and digital images, the effectiveness of the dermaheal in the treatment of diabetic ulcers will be assessed.
Settings and conduct
Diabetes Clinic - DRC
Participants/Inclusion and exclusion criteria
Study inclusion criteria :
1- Wegener G 1 and 2 diabetic ulcers
2 - 4 weeks old wound in the area of legs and extremities (toes, soles of the feet, heels, on the toes)
3 - Age: 18 to 80 years
4 - Body mass index: 35 -18
5 - Wound area: 1 to 30 square centimeters
6 - 0.7 ≤ ABI ≤ 1.2
7 - Being consciousness at the beginning of the study
Inclusion criteria:
1 - Smoking and drug addiction
2- Taking medications that may interfere with wound healing, such as corticosteroids, immunosuppressive agents, and cytotoxic agents
3 - Simultaneous disease that may have negatively affect wounds healing such as cancer, vasculitis, kidney and liver failure, advanced heart failure
Intervention groups
Placebo group (standard treatment
with Eucerin) and treatment group (standard treatment with Dermaheal ointment)
Main outcome variables
Area of ulcer
Wound color
Wound discharge
General information
Reason for update
Acronym
SDWHE
IRCT registration information
IRCT registration number:IRCT20080904001199N4
Registration date:2020-10-05, 1399/07/14
Registration timing:prospective
Last update:2020-10-05, 1399/07/14
Update count:0
Registration date
2020-10-05, 1399/07/14
Registrant information
Name
Mohammad Reza Amini
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 8822 0038
Email address
mramini@tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2020-10-22, 1399/08/01
Expected recruitment end date
2021-06-21, 1400/03/31
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Evaluation of Dermaheal Ointment Healing Effects on Diabetic Foot Ulcer: Double-Blind Randomized Clinical Trial Study
Public title
Dermaheal Effect on Diabetic Foot Ulcer
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Wagner G 1&2 Diabetic Foot Ulcer
Neuropathic and Neuroischemin Ulcer 0.7 ≤ ABI ≤ 1.2
Exclusion criteria:
Patient Disagreement to Participate
Use of Medications that can Interfere with Wound Healing such as Corticosteroids, Immunosuppressive agents, and Cytotoxic agents
Age
From 18 years old to 80 years old
Gender
Both
Phase
3
Groups that have been masked
Participant
Care provider
Outcome assessor
Data analyser
Sample size
Target sample size:
50
Randomization (investigator's opinion)
Randomized
Randomization description
The first step in the random process is to create a random sequence. The second step after creating a random sequence is to hide the generated sequence. To use the random number table, we must first determine the number of the table to read. The second is to consider numbers for different groups (for example, pair numbers for intervention A and individual numbers for intervention B, then hand over one of the numbers and move in one of the directions predetermined and record the numbers We assign to different groups. Blocking is usually used to create a balance in the number of specimens assigned to each of the groups studied, for example, in blocks of 4 that have two allocations to the intervention group and two allocations to the control group Is taken.
Blinding (investigator's opinion)
Double blinded
Blinding description
Given the fact that the treatments are prescribed as unprinted tubes, also the appearance of both ointments is similar in both control and intervention groups, the patient will not be informed about her/his assignment to the control or intervention group. Forasmuch as groups will be marked by letters A and B; and patient assignment to either A or B groups will be done using block randomization, therefore, the treating and wound assessor physician will not be informed of the patient's group assignment when examining the wound using a checklist. This will reduce the observation bias (data collection) which arises from mental presupposition. The second principal researcher will also be unaware of the grouping details. Finally, the statistician will statistically analyze the data without knowing the treatment assigned to group A or B. The First Principal researcher is not blinded and can reopen the codes and be informed about the received treatments of each patient (if necessary or and at the end of the study).
Placebo
Used
Assignment
Parallel
Other design features
No
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Institutional Research committee Endocrine & Metabolism Research Institute - Tehran University of Me
Street address
NO 10, Jalal-AL-Ahmad St., Chmaran HWY., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
14117-13137
Approval date
2020-09-23, 1399/07/02
Ethics committee reference number
IR.TUMS.EMRI.REC.1399.036
Health conditions studied
1
Description of health condition studied
Diabetic Foot Ulcer
ICD-10 code
E11.4
ICD-10 code description
Type 2 diabetes mellitus with neurological complications
Primary outcomes
1
Description
Ulcer Area
Timepoint
End of every week
Method of measurement
Images & and ruler
2
Description
Wound Discharge
Timepoint
End of every week
Method of measurement
Color, odor and amount by wound healing checklist
3
Description
Surrounding tissues
Timepoint
End of every week
Method of measurement
Color, hotness, edema and sense by wound healing checklist
Secondary outcomes
1
Description
ABI
Timepoint
End of treatment
Method of measurement
ABI measurement Device
2
Description
FBS
Timepoint
End of treatment
Method of measurement
Glucometer
3
Description
Pain severity
Timepoint
End of every week
Method of measurement
Visual pain scale
Intervention groups
1
Description
Intervention group: Dermaheal Ointment In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the dermaheal ointment will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive & a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Darmaheal ointment is a dressing based on herbal and natural products including Arnebia euchroma, thymes, Maticaria chamomilla L., Curcuma longa, wax, honey, and olive oil, which is produced by Darudarman Salafchegan Knowledge-Based Co.
Category
Treatment - Drugs
2
Description
Placebo group In the form of ready-to-use tubes without printing. The wound and surrounding tissues will be cleansed with saline solution and dried with sterile gauze. Then, the placebo dressing will be applied to the wound using an abaisse-langue and, fixed by the anti-allergic adhesive & a four-layer sterile dry gauze. Changing the dressing and applying the ointment should be done once a day for 4 weeks. Placebo dressing contains the inert substance Eucerin, which is produced by Darudarman Salafchegan Knowledge-Based Co.
Category
Placebo
Recruitment centers
1
Recruitment center
Name of recruitment center
Diabetes Clinic - DRC
Full name of responsible person
Kamelia Rambod
Street address
North Kargar st., Shahrivar St.
City
Tehran
Province
Tehran
Postal code
2222233333
Phone
+98 21 8822 0037
Email
rambod.camelia@gmail.com
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Darudarman Salafchegan Co. (Knowledge-based)
Full name of responsible person
Ali Shariatmadari
Street address
first floor- No. 66 – Tousi st. – Dr. Gharib st. – Keshavarz blvd. -Tehran
City
Tehran
Province
Tehran
Postal code
1419833371
Phone
+98 21 6690 9061
Email
Ali.sh1345@yahoo.com
Web page address
https://darudarmanco.com/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Darudarman Salafchegan Co. (Knowledge-based)
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry
Person responsible for general inquiries
Contact
Name of organization / entity
Endocrinology and Metabolism Research Institute
Full name of responsible person
Mohammad Reza Amini
Position
DF PhD
Latest degree
Ph.D.
Other areas of specialty/work
DF PhD Student
Street address
Dr. Shariati Hospital 5th floor
City
Tehran
Province
Tehran
Postal code
1411413137
Phone
+98 21 8822 0037
Email
mramini@tums.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Mohammad Reza Mohajeri Tehrani
Position
Professor
Latest degree
Subspecialist
Other areas of specialty/work
Endocrine
Street address
Dr. shariati Hospital
City
Tehran
Province
Tehran
Postal code
1411413137
Phone
+98 21 8822 0037
Email
mrmohajeri@tums.ac.ir
Web page address
http://emri.tums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Center for Knowledge-Based institutions and companies, Vice-Presidency for Science & Technology
Full name of responsible person
Pouya Salahi
Position
Researcher
Latest degree
Medical doctor
Other areas of specialty/work
Traditional Medicine
Street address
first floor- No. 66 – Tousi st. – Dr. Gharib st. – Keshavarz blvd. -Tehran
City
Tehran
Province
Tehran
Postal code
1419833371
Phone
+98 21 8822 0096
Email
Salahi.p93@gamil.com
Sharing plan
Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
ethical
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
Not applicable
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Title and more details about the data/document
Wound healing checklist, Images, ABI
When the data will become available and for how long
Per 3 month
To whom data/document is available
Dr. Mohammad Reza Amini
Under which criteria data/document could be used
Primary Evaluation of the Process and Under Certain Circumstances
From where data/document is obtainable
Ethics Committee endocrine & Metabolism Research institute - Tehran University of Medical Sciences
What processes are involved for a request to access data/document
Hand over to the Project Executor and he will refer to the Committee of Ethics